Navigation Links
HIFU (Ablation of Prostate Tissue with Sound Waves) Has Been Perfected for Prostate Cancer

In Search of HIFU Perfection – Is It Possible to Cure Aggressive Prostate Cancer? The answer is yes!

HIFU Centers of America (HIFU) and Dr. Ronald Wheeler are announcing the opening of their Flagship Center of HIFU Excellence in Sarasota, Florida. Dr. Wheeler, an accomplished HIFU specialist with more than 10 years of experience, has uniquely treated more than 500 men with prostate cancer using both, the Sonablate 500 technology as well as his preferred technology … Ablatherm from EDAP-TMS.

Dr. Wheeler believes HIFU perfection is possible but only with years of experience and an imaging skill set as well the implementation of an intellectual property. Through his thorough understanding of physics and the HIFU technology, Dr. Wheeler has accomplished something with prostate cancer that no one has ever done in more than 27 years of HIFU treatments worldwide. Specifically, Dr. Wheeler has cured 57 consecutive prostate cancer patients over the past 3 years with the Ablatherm technology providing evidence that the number one cancer contracted by men can be predictably cured. To assure the highest percentage for cure a patient must qualify with a PSA level of = 8.5 ng/ml, regardless of Gleason Score. Dr. Wheeler quickly points out that men with a PSA significantly higher than 8.5 ng/ml can still be cured but not 100% of the time.

Dr. Wheeler attributes his success to his imaging skills and his HIFU experience in combination with patient selection, the increasing use and acceptance of 3.0 Tesla Multi-parametric MRI scans diagnostically and his intellectual property soon to be patent pending. With the patent pending concept, Dr. Wheeler has figured out how to predictably cure prostate cancer especially with aggressive cancers where the need is the highest. Overall, there is a significant need to establish a predictable cure in HIFU as the rate of failures in the USA and around the world is 16-36% when treating low grade and intermediate cancers only. According to Dr. Wheeler, all prostate cancers grades including aggressive prostate cancer defined by a Gleason score of 7, 8, 9 or 10 can now be treated one time with a realistic expectation for cure. It is known that aggressive prostate cancers, make up approximately 35-40% of all prostate cancers. Dr. Wheeler’s research and validation is tantamount to a quantum leap for medical science as all men benefit from his research.

Dr. Wheeler’s success brings new relevance to the PSA blood test and contradicts the best recommendation from the US Preventative Services Task Force (USPSTF) to avoid PSA testing. According to Dr. Wheeler the PSA blood test is the marker of prostate disease activity similar to a thermometer reading, suggesting an illness … when elevated. The adverse events for HIFU are minimal with long term incontinence or impotency extremely rare while fistulas have been non-existent. Men interested in learning more are encouraged to find us on line at:, or call us toll free: 1-877-766-8400, where our niche market is curing aggressive prostate cancers.

Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related biology technology :

1. SonaCare Medical’s Sonablate® Performs Prostate HIFU in Huntersville, NC
2. Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer
3. ImaginAbs PSMA Imaging Agent Detects More Lesions Compared to Standard Imaging Methods for Detection of Prostate Cancer in Phase I/IIa Study
4. Prostate Cancer Foundation Launches First Competition for Stupski Prize in Prostate Cancer Computational Oncology
5. New study: Diet linked to prostate cancer survival
6. With fewer PSA screenings, will more men die of prostate cancer?
7. Generex Announces Memorandum of Understanding in respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine
8. SonaCare Medical Receives FDA Clearance for its Sonablate® High Intensity Focused Ultrasound Prostate Ablation Device
9. Aeterna Zentaris Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
10. Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize
11. September Is Prostate Cancer Awareness Month
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):